ABSTRACT. The possibility that group B streptococci (GBS) may induce neonatal neutropenia by promoting neutrophil aggregation and the entrapment of aggregates in the lung was studied in vivo and in vitro utilizing a cell free GBS extract [(GBS)-
GBS is a major cause of sepsis and meningitis in neonates. Neutropcnia is frequently associated with neonatal GBS infections. The causc for the reduction in circulating neutrophils is poorly understood. Pulmonary disease, which includes marked infiltration of PMNs into the alveoli and interstitium, is responsible for much of the morbidity associated with GBS infections in the neonate (I). Bacteremia and tissue invasion by live bacteria are important in the pathogenesis of GBS disease. The studies reported in this paper suggest that cell-free GBS antigens (2) may also play a role in neonatal GBS disease. The GBS extract reduced circulating numbers of PMNs and induced PMN sequestration in lamb lungs in vivo (3) and also aggregated human PMNs in an in vitro system. Antibody to GBS prevents PMN aggregation. During sepsis, GBS antigens may induce PMN aggregation and nonspecific entrapment in the pulmonary vasculature contributing to the neutropenia and pulmonary complications of GBS infections.
MATERIALS AND METHODS
Extruct. GBS type I11 (strain 878) was grown overnight in 3-liter batches in Todd-Hewitt broth (Difco Laboratories, Detroit, MI), centrifuged at 2500 x g for 10 min and the supernatant discarded. The bacterial button was resuspended in 200 ml of 2% TCA and stirred overnight at 4" C. The cell button was removed by centrifugation (2500 x g for 10 rnin), and 4 volumes of absolute ethanol was added to the supernatant. The mixture was stored overnight at 4" C and the fine precipitate removed by centrifugation and lyophilized (The Virtis Company, model 62 12-00 10, Gardiner, NY) (2). The final extract contained 10% protein, the remainder was carbohydrate including small amounts of group and type I11 carbohydrate as determined by capillary precipitation. Chromatographic carbohydrate fingerprints of the extract resembled those of whole GBS cells (2) . A Limulus lysate assay was done to rule out endotoxin contamination of the extract.
Lamb studies. Neonatal lambs, less than 7 days of age, of either sex were used. After local xylocaine anesthesia, a no. 5 French Swan-Ganz catheter was placed in the jugular vein and advanced into the pulmonary artery. A carotid artery was also cannulated. Pulmonary and systemic arterial pressures were measured with pressure transducers and blood samples were collected through the indwelling catheters.
All solutions were infused into the lambs' superior vena cava. Each received a bolus injection of GBS-TCA (I mg/kg) dissolved in 25 ml of normal saline. Three control lambs were infused Iieccivcd May 20, 1986 ; accepted November 13, 1986. only with 25 ml of normal saline. Blood specimens were taken to aggregate the cells. Each neutrophil suspension (0.4 ml) was placed in a cuvette with a siliconized stir bar, and equilibrated in the aggregometer at 37.5" C at a stir rate of 900 rpm.
Test solutions. Experimental solutions were prepared by incubation with serum or PBS in the same manner. After incubation at 37" C for 30 min, the test solutions (0.05 ml) were added to neutrophils in the aggregometer and the change in light transmission over 1 min was measured. The change in light transmission (AT) corresponds to aggregation of the cells.
Initial studie.~. GBS-TCA was incubated in serum for 30 min prior to addition to PMNs. The final concentrations of the extract in the aggregometer were 0.01 to 1 mg/ml. After the initial dose response studies with adult PMNs, GBS-TCA (1.0 mg/ml in serum or PBS) was individually tested with PMNs from eight adult volunteers. Serum alone was added to PMNs as a control.
To exclude TCA effect, TCA 2.5 to 25% was added to PBS and serum before addition to PMNs in the incubator. These cord blood specimens were tested at I . O mg/ml GBS-TCA in serum.
FoNow-up studies. Initial studies indicated that GBS-TCA would aggregate PMNs only in the presence of serum. Attempts were made to block aggregation by complement inactivation or by the addition of a GBS immunoglobulin. In these experiments a new source of human serum was utilized as the earlier lot had been depleted. The final extract concentration in these studies was 0.1 mg/ml as the new serum produced good aggregation curves at lower extract concentrations.
Immzrnoglohulin. GBS immune globulin (lot 004) was provided by the Sandoz Research Institute, Vienna, Austria. Adult human volunteers were immunized with a pentavalent GBS vaccine, their convalescent plasma pooled, alcohol fractionated, and the resultant IgG was processed by the Swiss Red Cross for intravenous administration (Sandoglobulin). To determine if GBS antibody in this preparation might prevent PMN aggregation, GBS-TCA was incubated with 10% GBS-immune globulin for 30 min (GBS-IgG) and added to serum. The mixture was then added to neutrophils in the aggregometer. In addition the inhibitory activity of commercially prepared intravenous y-globulin (Sandoglobulin lot 2.370.069.0) was examined.
Complement stzidies. Human serum was heated at 56" C for 30 min before or after the addition of GBS-TCA. In addition, 20 mM EGTA was added to serum prior to addition of extract.
In these experiments GBS-TCA in serum served as a paired control.
Statistical ana1ysi.s. Data were compared with a paired t test.
RESULTS
Animal studies. The intravenous infusion of GBS-TCA into 1-to 6-day-old lambs induced significant reductions in the total circulating white blood counts (3). A striking difference was observed in pulmonary histology in the lambs exposed to GBS-TCA as compared to controls. The pulmonary septae of control lambs were normal (Fig. 1 ). Lambs infused with GBS-TCA had widened alveolar septae, heavy neutrophilic infiltration of their interstitial spaces and pulmonary capillary congestion (Fig. 2) . Aggregalion siudie.~. Attempts to induce aggregation of PMNs with increasing concentrations of GBS-TCA in PBS were unsuccessful. However, prompt aggregation occurred when GBS-TCA was preincubated in whole serum. Figure 3 depicts the in vitro aggregation patterns observed with adult PMNs. The first curve, after an initial dilution effect, shows typical biphasic aggregationdeaggregation following exposure of adult PMNs to GBS-TCA in human serum. Biphasic PMN aggregation was not seen with GBS-TCA preincubated in PBS or serum without GBS-TCA
(curves 2 (and 3).
PMN aggregation, induced by GBS-TCA at various concentrations and following preincubation in human serum, is depicted in Table 1 . No aggregation was observed at 0.01 or 0.05 mg GBS-TCA/ml of serum. Aggregation occurred at 0.1, 0.5, and 1.0 mg/ml concentrations ( Table 2) . Aggregation did not occur with GBS-TCA in PBS with PMNs from eight different adults. However, a significant increase in aggregation was observed when GBS-TCA, preincubated in serum, was added to PMNs. Serum alone (Fig. 3) induced no aggregation (DT 3.56 + 1.59 SD, n = 9). Addition of concentrations of TCA 2.5 to 25% to serum induced precipitation of serum proteins. However, after centrifugation supernatants from these preparations did not aggregate PMNs; TCA (2.5 to 25%) in PBS also did not aggregate PMNs.
PMNs isolated from three human cord blood specimens were tested. Incubation of GBS-TCA in human serum at a concentration of 1.0 mg extract/ml serum resulted in the typical newborn pattern of irreversible aggregation (AT: 7, 12, and 14%). The mean increase in light transmission ( 1 1 % + 3.6 1 SD) was similar to the response of adult PMNs. Subsequent studies were conducted with a new serum source, with better attention toward the preservation of complement. With this serum 0.1 mg/ml of extract yielded good aggregation curves so this concentration was used in contrast to the initial studies with I mg/ml. Figure 4 depicts the characteristic biphasic aggregation (curve I ) observed with adult neutrophils exposed to GBS-TCA in human serum. The second curve is representative of the significant reduction in aggregation with GBS immune globulin as compared to control GBS-TCA in serum (Table 3) . In contrast (curve 3), when Sandoglobulin lot 2.370.069.0 was used with GBS-TCA, augmented irreversible aggregation of PMNs occurred (mean AT 1 1.63 + 2.56 SD versus 1 1.75 + 2.42 SD control, n = 4, NS).
Further studies examined whether heat treatment of serum altered PMN aggregation. The curve in Figure 4 depicts the inhibition of aggregation following heat inactivation of serum before incubation with GBS-TCA. However, when GBS-TCA was first incubated in serum prior to heating (56" C for 30 min), aggregation was unchanged as compared to controls (Table 4) . Twenty mM EGTA also significantly decreased aggregation (mean AT 6.25 + 3.2 versus 15.6 & 4.9 control, p = 0.008).
DISCUSSION
Early onset neonatal GBS sepsis often results in shock, pneumonia, and neutropenia in afflicted infants. Several studies demonstrate that sterile cell-free extracts of GBS produce similar effects when infused into lambs and piglets (2, 3, 6, 7) . In this study, a TCA extract of GBS strain 878 (type 111) induced reductions in white blood cell counts and a marked accumulation of PMNs in the pulmonary interstitia of newborn lambs. The extract also aggregated human PMNs in vitro in the presence of serum. If intravascular PMN aggregates were formed during human neonatal GBS bacteremia, trapping of the aggregates might occur in the pulmonary microvasculature. A secondary inflammatory response might enhance local pulmonary injury as has been described in adult respiratory distress syndrome and in patients on hernodialysis (8) (9) (10) . The removal of PMNs from the circulation by this mechanism might deplete PMN reserves Fig. 4 . Studies of inhibition of neutrophil aggregation by group B streptococcal cxtract. Thc typical aggregation-deaggregation curve is seen with GBS-TCA in serum (I) . If the GBS-TCA was first exposed to IgG (GBS immune globulin) thc resultant preparation did not cause aggregation (2) . Mixing of GBS-TCA with standard Sandoglobulin resulted in augmented irreversible aggregation (3) . Heat inactivation of serum prior to the addition of GBS-TCA also prevented neutrophil aggregation (4). Concentration extract 0.1 mg/ml. * GBS-TCA -final concentration -0.1 mg/ml.
(1 1) in the neonate whose marrow progenitors already may have limited potential to respond ( 12) . Human neonatal PMNs aggregate differently in vitro than adult PMNs. In previous reports a pattern of irreversible aggregation has been seen when neonatal PMNs were exposed to chemotactic peptides such as FMLP (13, 14) . When neonatal PMNs irreversibly aggregate, the effect may not be transient. Aggregates may become entrapped in the pulmonary microvasculature, disintegrate, and release toxic products. However, the presence of fresh serum was a potent stimulus for PMN aggregation. Serum alone did not induce aggregation. TCA did not aggregate neutrophils or activate serum to induce neutrophi1 aggregation. The initial studies were done with a single serum source. As there had been frequent freeze-thawing of that serum, another lot of serum was obtained and utilized a manner to preserve complement. The new serum induced comparable aggregation curves at 10-fold lower extract concentrations suggesting that complement activation and C5a might be responsible for aggregation. It is known that complement, specifically C5a, will aggregate PMNs in vitro (1 5-17 ). C5a appears to be stable after heating at 56" C for 30 min, whereas whole complement is inactivated (5) . Heat inactivation of serum, prior to the addition of GBS-TCA, abrogated the aggregation of PMNs. If GBS-TCA were incubated in serum containing complement and then the mixture were heated a biphasic aggregation-deaggregation PMN curve was seen. Therefore, heat labile complement may be converted to heat stable C5a in the presence of GBS-TCA. Activation of complement by GBS may play a role in the aggregation of PMNs in vivo and contribute to the localization of PMNs in the pulmonary interstitium. A deficiency of GBS antibody increases the risk of serious neonatal GBS infections. Conversely adequate amounts of circulating GBS antibody may enhance survival in septic premature infants (18) . The role of antibody in preventing or improving survival in GBS discasc has been thought to be secondary to its ability to enhance phagocytosis and killing of bacteria (19, 20) . In this study GBS immune globulin appeared to interupt PMN aggregation in vitro. In contrast, a standard immunoglobulin preparation augmented aggregation. It is possible that hyperimmune GBS globulin may limit pulmonary damage caused by PMN aggregates. Further work needs to be done to better understand the relevance of these observations.
